EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in Antiviral Drug Development Targeting Viral Proteases

Yuanyuan Zhang iD, Jiaxin Chen iD, Jiaqi Li iD, Zhongxin Xu iD, Jing Wang iD, Luqing Shang iD

Medicinal Research Reviews · 2026

DOI: 10.1002/med.70075 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, 2026. Verfasst von Yuanyuan Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, KLMDASR of Tianjin and Drug Discovery Center for Infectious Disease, Nankai …. Hauptthemen laut MEDLINE: Antiviral Agents, Drug Development, Protease Inhibitors, Viral Proteases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 146 Literaturangaben. Gefördert von: National Natural Science Foundation of China, R&D Program of Guangzhou Laboratory, Fundamental Research Funds for the Central Universities, Nankai University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Viral proteases are critical targets in antiviral drug development due to their essential role in the viral lifecycle and high conservation across viral strains. This review summarizes the recent progress of antiviral drugs based on protease structures, with a focus on the structural characteristics and inhibitor design strategies targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2), Enterovirus 71 (EV71), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV). Based on the three‐dimensional structure of proteases, various types of protease inhibitors such as peptidomimetic, non‐peptidic, and natural product‐derived inhibitors are discussed. Given the critical challenge of drug resistance in antiviral therapies, we address the mechanisms of protease inhibitor resistance and explore advanced strategies, including allosteric inhibition, dual‐target inhibition, and Proteolysis‐Targeting Chimeras (PROTAC) to overcome drug resistance. This review also explores the cutting‐edge applications of artificial intelligence (AI) for viral protease‐based antiviral drug discovery, providing valuable insights for the rational design and development of antiviral drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsDrug DevelopmentProtease InhibitorsViral ProteasesViral Protease InhibitorsHumansDrug Resistance, ViralAnimals

Stichwörter der Autor:innen

Artificial intelligenceDrug resistancePROTACsProtease inhibitorsViral proteases

Substanzen

Antiviral AgentsProtease InhibitorsViral ProteasesViral Protease Inhibitors

Autor:innen und Institutionen

  • State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, KLMDASR of Tianjin and Drug Discovery Center for Infectious Disease, Nankai University, Tianjin, China.

ORCID-Profile: Yuanyuan Zhang, Jiaxin Chen, Jiaqi Li, Zhongxin Xu, Jing Wang, Luqing Shang

Förderung

  • National Natural Science Foundation of China
  • R&D Program of Guangzhou Laboratory
  • Fundamental Research Funds for the Central Universities, Nankai University

Zitieren

APA

Zhang, Y., Chen, J., Li, J., Xu, Z., Wang, J., & Shang, L. (2026). Advances in Antiviral Drug Development Targeting Viral Proteases. Medicinal Research Reviews. https://doi.org/10.1002/med.70075

Vancouver

Zhang Y, Chen J, Li J, Xu Z, Wang J, Shang L. Advances in Antiviral Drug Development Targeting Viral Proteases. Medicinal Research Reviews. 2026. doi:10.1002/med.70075

BibTeX
@article{Zhang2026,
  author = {Zhang, Yuanyuan and Chen, Jiaxin and Li, Jiaqi and Xu, Zhongxin and Wang, Jing and Shang, Luqing},
  title = {Advances in Antiviral Drug Development Targeting Viral Proteases},
  journal = {Medicinal Research Reviews},
  year = {2026},
  doi = {10.1002/med.70075}
}
Kostenlos starten →